NCT04038437 - A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 15, 2019

Primary Completion Date

April 26, 2022

Study Completion Date

September 24, 2022

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

CPX-351

CPX-351 will be administered on Days 1 and 3 of each cycle

DRUG

Venetoclax

Venetoclax will be adminstered on Days 2 to 21 of each cycle

Trial Locations (8)

MUSC Hollings Cancer Center, Charleston

Blood & Marrow Transplant Group of Georgia, Atlanta

Washington University School of Medicine, St Louis

University of Kansas Medical Center, Kansas City

City of Hope, Duarte

Oregon Health & Science University, Portland

Fred Hutchinson Cancer Research Center, Seattle

Dana Farber/ Brigham & Women's Cancer Center, Boston